patients taking isradipine (DynaCirc) have a higher risk of angina

The several studies about calcium blockers over the last year have raised huge questions about their safety.

That's why there's so much interest in a brand-new study in JAMA that suggests patients taking isradipine (DynaCirc) have a higher risk of angina...and other adverse events.

These unexpected results come from a study that was designed for a DIFFERENT purpose...to see if either isradipine or HCTZ slows the development of atherosclerosis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote